However, they ascribed this result to rivaroxaban blocking a reduction in anti‐tumour immunity caused by FXa‐producing myeloid cells, as evidenced by further reduction in tumour growth observed in checkpoint inhibitor plus rivaroxaban combination.19 The gene discussed is F10; the disease is neoplasm.